CN107088199A - α glucosidase inhibitors and its application - Google Patents
α glucosidase inhibitors and its application Download PDFInfo
- Publication number
- CN107088199A CN107088199A CN201710403890.4A CN201710403890A CN107088199A CN 107088199 A CN107088199 A CN 107088199A CN 201710403890 A CN201710403890 A CN 201710403890A CN 107088199 A CN107088199 A CN 107088199A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- diabetes
- preventing
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XZONDNKJYQKBEK-UHFFFAOYSA-N CCC(C1)C(CO)OC1N(C=CC(N1)=S)C1=O Chemical compound CCC(C1)C(CO)OC1N(C=CC(N1)=S)C1=O XZONDNKJYQKBEK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of α glucosidase inhibitors, including：4 thio 2' BrdUs.The α glucosidase inhibitors are used for the medicine or prodrug for preparing preventing and treating type II diabetes.The α glucosidase inhibitors that the present invention is provided can effectively suppress the activity of α glucuroides, and then effectively reduce type II diabetes people's postprandial blood sugar content.Present invention also offers the medicine prepared using α glucosidase inhibitors for preventing and treating type II diabetes, count by weight, the medicine includes：4 thio 5 10 parts of 2' BrdUs, the second 80 90 parts of active ingredient of Chinese herbs.The above-mentioned α glucosidase inhibitors that the present invention is provided carry out the blood sugar reducing health medicine that rational proportion is prepared into effectively preventing and treating type II diabetes with other second active ingredient of Chinese herbs, after medication in 12 weeks, cure-remarkable-effectiveness rate to patients with NIDDM is 42.7%, effective percentage up to 95.2%.
Description
Technical field
The present invention relates to pharmaceutical technology field, more particularly to a kind of alpha-glucosidase restrainer and its application.
Background technology
Diabetes are a kind of endocrine and metabolic disorders disease of generation in worldwide scope, and it is due to human insulin
It is a kind of commonplace chronic disease, it is mainly characterized by hyperglycaemia caused by diacrisis and islet function damage.With cancer
Disease, angiocardiopathy are considered as worldwide three big diseases jointly, and it is caused by the interaction of the composite factors such as h and E
Common disease.Diabetes not only cause hyperglycemia, and long term hyperglycemia and metabolic disorder etc. are also possible to human body can be caused to be permitted
The diabetic complication of many tissues and organ, such as diabetic cataract, atherosclerosis, peripheral nerve disease, kidney trouble
Change and PVR etc..So that the healthy of people, work and life etc. are by very big threat.
Clinically, diabetes are divided into four types, i.e.,：I type glycosuria is divided into according to the dependence situation difference to insulin
Sick (dependences), type II diabetes (independent of), also other specific types and gestational diabetes.
In the past few decades, the quantity of diabetes (DM) people constantly accelerates, and in the case quantity of 2010
The whole world 2.85 hundred million is reached.Wherein in most cases, it is type II diabetes (T2DM)。
The quantity of nearly 3 years diabetes patients is even more sharp increase, according to IDF (IDF) statistics of 2013
Report, whole world maturity-onset diabetes number has 3.82 hundred million, wherein 95% belongs to type II diabetes.
The pathogenesis of type II diabetes is extremely complex, and Western medicine is directed to different ill mechanism, and its action target spot is more clear
Chu, effect is stronger.But, patients with NIDDM is the entirety of an organic connections, many metabolism of diabetic's body
There is imbalance in link, a certain target drug is acted on merely and is difficult to play optimum therapeuticing effect, brings side effect also relative simultaneously
Substantially, primary failure, secondary failure problem are also more serious.Application has overall if we are in type II diabetes early stage
Regulation and Mutiple Targets medicine certainly will improve therapeutic effect, symptom management development and the generation for reducing complication.Therefore, study
Integrally-regulated, Mutiple Targets treatment and the low medicine of side effect turn into a direction of type II diabetes drug research.
The content of the invention
It is an object of the invention to solve at least the above, and provide the advantage that at least will be described later.
It is a still further object of the present invention to provide a kind of new alpha-glucosidase restrainer, its can effectively suppress α-
The activity of glucuroide, and then effectively reduce type II diabetes people's postprandial blood sugar content.
It is a still further object of the present invention to provide a kind of application of alpha-glucosidase restrainer, by itself and others second
Active ingredient of Chinese herbs carries out the blood sugar reducing health medicine that rational proportion is prepared into effectively preventing and treating type II diabetes.
In order to realize according to object of the present invention and further advantage there is provided a kind of alpha-glucosidase restrainer,
Including：
Thio -2'- the BrdUs of 4-, its structural formula is
Preferably, the medicine or prodrug of type II diabetes are prevented and treated for preparing.
Alpha-glucosidase restrainer as described above is preparing the application in being used to prevent and treat the medicine of type II diabetes.
It is a kind of to apply alpha-glucosidase restrainer as described above to prepare the medicine for preventing and treating type II diabetes, by weight
Number meter is measured, the medicine includes：5-10 parts of 4- thio -2'- BrdUs, the second 80-90 parts of active ingredient of Chinese herbs.
Preferably, count by weight, the medicine includes：5-10 parts of 4- thio -2'- BrdUs, the second Chinese medicine
80-90 parts of active component.
Preferably, count by weight, second active ingredient of Chinese herbs be 10-15 parts of radix glycyrrhizae, 13-17 parts of the wind-weed,
22-27 parts of mulberry leaf, 3-8 parts of the root of kudzu vine, 13-15 parts of corn stigma, 5-9 parts of the coptis, 14-19 parts of the dried rhizome of rehmannia, 4-8 parts of Chinese cassia tree, Inonotus obliquus
2-4 parts, 28-32 parts of dandelion, 7-12 part of grass of march, 1-3 parts of ginkgo leaf, 2-5 parts of purple perilla, 2-7 parts of bidens pilosa, it is purple to carry on the back day
13-16 parts of certain herbaceous plants with big flowers, the mixture for the extract that 6-10 parts and small winged lotus 2-4 parts of aizoon stonecrop.
Preferably, count by weight, second active ingredient of Chinese herbs be 13-15 parts of radix glycyrrhizae, 15-17 parts of the wind-weed,
22-23 parts of mulberry leaf, 3-4 parts of the root of kudzu vine, 13-15 parts of corn stigma, 5-6 parts of the coptis, 14-16 parts of the dried rhizome of rehmannia, 4-5 parts of Chinese cassia tree, Inonotus obliquus 2
Part, 28-29 parts of dandelion, 7-9 parts of grass of march, 1-2 parts of ginkgo leaf, 2-3 parts of purple perilla, 2-4 parts of bidens pilosa, Gynura bicolor 13
Part, the mixture for the extract that 6-8 parts and small winged lotus 2-4 parts of aizoon stonecrop.
Preferably, count, count by weight by weight, second active ingredient of Chinese herbs is 15 parts of radix glycyrrhizae, known
Female 17 parts, 22 parts of mulberry leaf, 3 parts of the root of kudzu vine, 15 parts of corn stigma, 6 parts of the coptis, 16 parts of the dried rhizome of rehmannia, 4 parts of Chinese cassia tree, 2 parts of Inonotus obliquus, Pu Gong
28 parts of English, 7 parts of march grass, 2 parts of ginkgo leaf, 2 parts of purple perilla, 4 parts of bidens pilosa, 13 parts of Gynura bicolor, 8 parts of aizoon stonecrop and small
Fly the mixture of the extract of 2 parts of lotus.
Preferably, the formulation of the medicine is selected from through gastrointestinal administration formulation or injecting medicine-feeding form.
Preferably, the medicine also includes being mixed with pharmaceutically acceptable auxiliary material.
Preferably, the auxiliary material be selected from solvent, propellant, solubilizer, cosolvent, emulsifying agent, binder, disintegrant,
Filler, lubricant, wetting agent, osmotic pressure regulator, stabilizer, glidant, flavouring, preservative, suspending agent, coating material
Material, aromatic, anti-binder, integrated agent, penetration enhancer, pH value regulator, buffer, plasticizer, surfactant, foaming
Agent, defoamer, thickener, inclusion agents, NMF, absorbent, diluent, flocculant and deflocculant, filter aid, release retardance
Any one or a few in agent.
Alpha-glucosidase (EC 3.2.1.20；α-glucosidase) it is a kind of be located in small intestinal mucosa cell brush border
Glucosides metabolic enzyme, be that a class can be from the total of the enzyme of the non-reducing end catalysis hydrolyzation of glucose base containing α-glycosidic bond substrate
Claim.
The experience such as polysaccharide is decomposed into monose after digesting step by step by alpha-glucosidase etc., is absorbed to after blood and eventually becomes
Blood glucose.Diabetes often show postprandial hyperglycemia in pathogenic process, for patients with NIDDM, and control is after the meal
Blood glucose is extremely important, and alpha-glucosidase turns into regulation and control postprandial blood sugar medicine as the key enzyme for adjusting food source blood glucose
The effect target enzyme of thing.
Alpha-glucosidase restrainer acts on alpha-glucosidase, suppresses its activity, hinders point of carbohydrate
Solution, influences the generation and absorption of glucose, finally reduces postprandial blood sugar, therefore as a line for the treatment of type II diabetes now
Oral hypoglycemic drug, plays the effect of key in the metabolic process of body.
The present invention at least includes following beneficial effect：
The new alpha-glucosidase restrainer that the present invention is provided, it can effectively suppress the work of alpha-glucosidase
Property, and then effectively reduce type II diabetes people's postprandial blood sugar content；It is reasonable that itself and other second active ingredient of Chinese herbs are carried out
Proportioning is prepared into the blood sugar reducing health medicine of effectively preventing and treating type II diabetes；
The present invention is under guidance of traditional Chinese medicine theory, and preferably several Chinese medicines are as the second active ingredient of Chinese herbs, and the science of being subject to is matched somebody with somebody
5, make, each medicine is cooperated, learn from other's strong points to offset one's weaknesses, act synergistically, all medicines share is treated both principal and secondary aspect of disease, heightened the effect of a treatment；
Chinese medicine material small toxicity used of the invention, overcomes the toxic side effect of other hypoglycemic medicines particularly Western medicine, and its
The shortcoming of the infringement after Western medicine to liver kidney is used for a long time；
The medicine of preventing and treating type II diabetes through zoopery and the clinical verification present invention can make patients with NIDDM empty
Abdomen blood glucose and after the meal 2 hours blood glucoses are reduced, and it is longer to hold time, while also make high fat of blood person's cholesterol and triglycerides drop
It is low, it is evident in efficacy；
Scientific formula, raw material is easy to get, and generation technique is advanced, simple and easy to do, workable, moderate product price, is adapted to
Preparation of industrialization；Can be according to the effective ingredient, property and formulation requirements of each Chinese medicine, using water extraction, physics in preparation process
Sterilizing methods, thus product active constituent content is high, it is stable, it is unlikely to deteriorate, is conducive to long-term preservation；
In summary, the new alpha-glucosidase restrainer that the present invention is provided can effectively suppress alpha-glucosidase
Activity, itself and other second active ingredient of Chinese herbs are subjected to the hypoglycemic that rational proportion is prepared into effectively preventing and treating type II diabetes
Health medicine；And the medicament composing prescription is reasonable, rich using safe, evident in efficacy, Small side effects, moderate cost, easy to make, medicine source
Rich, convenient to take, raw material is easy to get, and generation technique is advanced, workable.
Further advantage, target and the feature of the present invention embodies part by following explanation, and part will also be by this
The research and practice of invention and be understood by the person skilled in the art.
Embodiment
With reference to embodiment, the present invention is described in further detail, to make those skilled in the art with reference to specification
Word can be implemented according to this.
It should be appreciated that such as " having ", "comprising" and " comprising " term used herein do not allot one or many
The presence or addition of individual other elements or its combination.
The present invention provides a kind of alpha-glucosidase restrainer, including：
Thio -2'- the BrdUs of 4-, its structural formula isExperiment proves that, the thio -2'- deoxidations of 4-
Uridine is up to 58.41% to the inhibitory activity of alpha-glucosidase.
In one preferred scheme, medicine or prodrug for preparing preventing and treating type II diabetes.
Alpha-glucosidase restrainer as described above is preparing the application in being used to prevent and treat the medicine of type II diabetes.
It is a kind of to apply alpha-glucosidase restrainer as described above to prepare the medicine for preventing and treating type II diabetes, by weight
Number meter is measured, the medicine includes：5-10 parts of 4- thio -2'- BrdUs, the second 80-90 parts of active ingredient of Chinese herbs.
In one preferred scheme, count by weight, the medicine includes：5-10 parts of 4- thio -2'- BrdUs, the
Two 80-90 parts of active ingredient of Chinese herbs.
In one preferred scheme, count by weight, second active ingredient of Chinese herbs is 10-15 parts of radix glycyrrhizae, wind-weed 13-
17 parts, 22-27 parts of mulberry leaf, 3-8 parts of the root of kudzu vine, 13-15 parts of corn stigma, 5-9 parts of the coptis, 14-19 parts of the dried rhizome of rehmannia, 4-8 parts of Chinese cassia tree, birch it is brown
2-4 parts of pore fungi, 28-32 parts of dandelion, 7-12 parts of grass of march, 1-3 parts of ginkgo leaf, 2-5 parts of purple perilla, 2-7 parts of bidens pilosa are purple
Carry on the back 13-16 parts of semiaquilegia adoxoides, the mixture for the extract that 6-10 parts and small winged lotus 2-4 parts of aizoon stonecrop.
In one preferred scheme, count by weight, second active ingredient of Chinese herbs is 13-15 parts of radix glycyrrhizae, wind-weed 15-
17 parts, 22-23 parts of mulberry leaf, 3-4 parts of the root of kudzu vine, 13-15 parts of corn stigma, 5-6 parts of the coptis, 14-16 parts of the dried rhizome of rehmannia, 4-5 parts of Chinese cassia tree, birch it is brown
2 parts of pore fungi, 28-29 parts of dandelion, 7-9 parts of grass of march, 1-2 parts of ginkgo leaf, 2-3 parts of purple perilla, 2-4 parts of bidens pilosa, the purple back of the body
13 parts of semiaquilegia adoxoides, the mixture for the extract that 6-8 parts and small winged lotus 2-4 parts of aizoon stonecrop.
In one preferred scheme, count, count by weight by weight, second active ingredient of Chinese herbs is radix glycyrrhizae 15
Part, 17 parts of the wind-weed, 22 parts of mulberry leaf, 3 parts of the root of kudzu vine, 15 parts of corn stigma, 6 parts of the coptis, 16 parts of the dried rhizome of rehmannia, 4 parts of Chinese cassia tree, 2 parts of Inonotus obliquus,
28 parts of dandelion, 7 parts of march grass, 2 parts of ginkgo leaf, 2 parts of purple perilla, 4 parts of bidens pilosa, 13 parts of Gynura bicolor, 8 parts of aizoon stonecrop
With the mixture of the extract of small winged 2 parts of lotus.
In one preferred scheme, the formulation of the medicine is selected from through gastrointestinal administration formulation or injecting medicine-feeding form.
In one preferred scheme, the medicine also includes being mixed with pharmaceutically acceptable auxiliary material.
In one preferred scheme, the auxiliary material is selected from solvent, propellant, solubilizer, cosolvent, emulsifying agent, binder, collapsed
Solve agent, filler, lubricant, wetting agent, osmotic pressure regulator, stabilizer, glidant, flavouring, preservative, suspending agent, bag
Clothing material, aromatic, anti-binder, integrated agent, penetration enhancer, pH value regulator, buffer, plasticizer, surfactant,
Foaming agent, defoamer, thickener, inclusion agents, NMF, absorbent, diluent, flocculant and deflocculant, filter aid, release
Any one or a few in retarding agent.
Embodiment 1
The medicine for preventing and treating type II diabetes is prepared using alpha-glucosidase restrainer, is counted by weight, it is described
Medicine includes：5 parts of the thio -2'- BrdUs of 4-, the second 80 parts of active ingredient of Chinese herbs；Wherein count by weight, 80 part second
Active ingredient of Chinese herbs be 10 parts of radix glycyrrhizae, 13 parts of the wind-weed, 22 parts of mulberry leaf, 3 parts of the root of kudzu vine, 13 parts of corn stigma, 5 parts of the coptis, 14 parts of the dried rhizome of rehmannia,
4 parts of Chinese cassia tree, 2 parts of Inonotus obliquus, 28 parts of dandelion, 7 parts of march grass, 1 part of ginkgo leaf, 2 parts of purple perilla, 2 parts of bidens pilosa, the purple back of the body
The mixture of the extract of 13 parts of semiaquilegia adoxoides, 6 parts of aizoon stonecrop and small winged 2 parts of lotus.
According to said medicine formula preparation piece agent person's capsule, the thio -2'- BrdUs of 4- contains in tablet or capsule
Measure as 5-6mg/g, the content of the second active ingredient of Chinese herbs is 80-83mg/g.
Embodiment 2
The medicine for preventing and treating type II diabetes is prepared using alpha-glucosidase restrainer, is counted by weight, it is described
Medicine includes：7 parts of the thio -2'- BrdUs of 4-, the second 84 parts of active ingredient of Chinese herbs；Wherein count by weight, 84 part second
Active ingredient of Chinese herbs be 14 parts of radix glycyrrhizae, 16 parts of the wind-weed, 23 parts of mulberry leaf, 4 parts of the root of kudzu vine, 15 parts of corn stigma, 5 parts of the coptis, 14 parts of the dried rhizome of rehmannia,
5 parts of Chinese cassia tree, 2 parts of Inonotus obliquus, 28 parts of dandelion, 7 parts of march grass, 2 parts of ginkgo leaf, 2 parts of purple perilla, 2 parts of bidens pilosa, the purple back of the body
The mixture of the extract of 13 parts of semiaquilegia adoxoides, 7 parts of aizoon stonecrop and small winged 3 parts of lotus.
Thio -2'- the BrdUs of 4- in piece agent or capsule, tablet or capsule are prepared according to said medicine formula
Content is 6-7mg/g, and the content of the second active ingredient of Chinese herbs is 83-85mg/g.
Embodiment 3
The medicine for preventing and treating type II diabetes is prepared using alpha-glucosidase restrainer, is counted by weight, it is described
Medicine includes：10 parts of the thio -2'- BrdUs of 4-, the second 90 parts of active ingredient of Chinese herbs；Wherein count by weight, 90 part
Two active ingredient of Chinese herbs are 15 parts of radix glycyrrhizae, 17 parts of the wind-weed, 22 parts of mulberry leaf, 3 parts of the root of kudzu vine, 15 parts of corn stigma, 6 parts of the coptis, the dried rhizome of rehmannia 16
Part, 4 parts of Chinese cassia tree, 2 parts of Inonotus obliquus, 28 parts of dandelion, 7 parts of march grass, 2 parts of ginkgo leaf, 2 parts of purple perilla, 4 parts of bidens pilosa,
The mixture of the extract of 13 parts of Gynura bicolor, 8 parts of aizoon stonecrop and small winged 2 parts of lotus.
Thio -2'- the BrdUs of 4- in piece agent or capsule, tablet or capsule are prepared according to said medicine formula
Content is 10mg/g, and the content of the second active ingredient of Chinese herbs is 90mg/g.
Embodiment 4
The medicine for preventing and treating type II diabetes is prepared using alpha-glucosidase restrainer, is counted by weight, it is described
Medicine includes：8 parts of the thio -2'- BrdUs of 4-, the second 88 parts of active ingredient of Chinese herbs；Wherein count by weight, 88 part second
Active ingredient of Chinese herbs be 15 parts of radix glycyrrhizae, 17 parts of the wind-weed, 23 parts of mulberry leaf, 4 parts of the root of kudzu vine, 15 parts of corn stigma, 6 parts of the coptis, 16 parts of the dried rhizome of rehmannia,
5 parts of Chinese cassia tree, 2 parts of Inonotus obliquus, 29 parts of dandelion, 9 parts of march grass, 2 parts of ginkgo leaf, 3 parts of purple perilla, 4 parts of bidens pilosa, the purple back of the body
The mixture of the extract of 13 parts of semiaquilegia adoxoides, 8 parts of aizoon stonecrop and small winged 4 parts of lotus.
Thio -2'- the BrdUs of 4- in piece agent or capsule, tablet or capsule are prepared according to said medicine formula
Content is 10mg/g, and the content of the second active ingredient of Chinese herbs is 90mg/g.
First, case standard is selected：
1. meet type II diabetes diagnostic criteria and TCM syndrome diagnostic criteria person.
2. between 18~70 years old age, male or female.
After 3. the introduction period terminates, blood glucose still reaches following standard：Fasting blood-glucose >=7.0mmol/L, and≤13.9mmol/L
And (or) 2 hours blood glucoses >=11.1mmol/L, and≤16.6mmol/L after the meal.And under conditions of blood glucose meets inclusion criteria,
Glycosylated hemoglobin person between 6.5% to 10.0%.
2nd, diagnostic criteria：
All have 1~3 case standard, and meets type II diabetes diagnostic criteria and TCM syndrome diagnostic criteria person, warp
Blood glucose assessment can be diagnosed as patients with NIDDM；And treated to the medicine of embodiment 1-4 in the present invention.
3rd, therapeutic scheme：
4 groups of experimental groups are set in the treatment, and 4 groups of experimental groups are the tablet or capsule prepared according to above-described embodiment 1-4, often
Oral 3 times of day, 2 every time, 12 weeks statistics curative effects；
Comprise only the second active ingredient of Chinese herbs of the present invention in control group, control group medicine, daily oral 3 times, every time 2
Grain, 12 weeks statistics curative effects are simultaneously contrasted with this experimental group；
Control group is identical with experimental group formulation, and dosage used in the second active ingredient of Chinese herbs is identical
4th, efficacy assessment standard
(1) it is effective：Decline more than 40% before fasting blood-glucose is relatively treated after treatment or be down to normal level (6.1mmol/L).
(2) effectively：Decline more than 20%, but not up to effective standard before fasting blood-glucose is relatively treated after treatment.
(3) it is invalid：Blood glucose, which declines, is not up to above-mentioned standard.
5th, statistical procedures：
Test group 1 100, fully recovers 15, effective 20, effective 56, no effect 9, and cure-remarkable-effectiveness rate 35% is efficient
91%；
Test group 2 158, fully recovers 18, effective 31, effective 95, invalid 14, and cure-remarkable-effectiveness rate 31% is efficient
92%；
Test group 3 124, fully recovers 25, effective 28, effective 65, invalid 6, and cure-remarkable-effectiveness rate 42.7% is efficient
95.2%；
Test group 4 118, fully recovers 18, effective 22, effective 66, invalid 12, and cure-remarkable-effectiveness rate 33.8% is efficient
90%；
Control group 114, fully recovers 10, effective 21, effective 55, invalid 28, and cure-remarkable-effectiveness rate 27.1% is efficient
75.4%；Integrated comparative, cure-remarkable-effectiveness rate, efficient comparing difference significantly (P ＜ 0.05), as a result show that test group is treated between two groups of groups
Improve tcm syndrome curative effect and be better than control group.
Note：Cure-remarkable-effectiveness rate=(clinic control recovery from illness+effective)/total number of cases × 100%, efficient=(clinic control recovery from illness+aobvious
Effect+effectively) × 100%
Although embodiment of the present invention is disclosed as above, it is not restricted in specification and embodiment listed
With it can be applied to various suitable the field of the invention completely, can be easily for those skilled in the art
Other modification is realized, therefore under the universal limited without departing substantially from claim and equivalency range, the present invention is not limited
In specific details and shown here as the embodiment with description.
Claims (10)
1. a kind of alpha-glucosidase restrainer, it is characterised in that including：
Thio -2'- the BrdUs of 4-, its structural formula is
2. alpha-glucosidase restrainer as claimed in claim 1, it is characterised in that for preparing preventing and treating type II diabetes
Medicine or prodrug.
3. alpha-glucosidase restrainer as claimed in claim 1 is being prepared for preventing and treating answering in the medicine of type II diabetes
With.
4. a kind of apply alpha-glucosidase restrainer as claimed in claim 1 to prepare the medicine for preventing and treating type II diabetes
Thing, it is characterised in that count by weight, the medicine includes：5-10 parts of 4- thio -2'- BrdUs, the second active Chinese drug component
80-90 parts of composition.
5. application alpha-glucosidase restrainer prepares the medicine for preventing and treating type II diabetes as claimed in claim 4, its
It is characterised by, counts by weight, second active ingredient of Chinese herbs is 10-15 parts of radix glycyrrhizae, 13-17 parts of the wind-weed, mulberry leaf 22-27
Part, 3-8 parts of the root of kudzu vine, 13-15 parts of corn stigma, 5-9 parts of the coptis, 14-19 parts of the dried rhizome of rehmannia, 4-8 parts of Chinese cassia tree, 2-4 parts of Inonotus obliquus, Pu Gong
28-32 parts of English, 7-12 parts of grass of march, 1-3 parts of ginkgo leaf, 2-5 parts of purple perilla, 2-7 parts of bidens pilosa, 13-16 parts of Gynura bicolor,
The mixture for the extract that 6-10 parts and small winged lotus 2-4 parts of aizoon stonecrop.
6. application alpha-glucosidase restrainer prepares the medicine for preventing and treating type II diabetes as claimed in claim 5, its
It is characterised by, counts by weight, second active ingredient of Chinese herbs is 13-15 parts of radix glycyrrhizae, 15-17 parts of the wind-weed, mulberry leaf 22-23
Part, 3-4 parts of the root of kudzu vine, 13-15 parts of corn stigma, 5-6 parts of the coptis, 14-16 parts of the dried rhizome of rehmannia, 4-5 parts of Chinese cassia tree, 2 parts of Inonotus obliquus, dandelion
28-29 parts, march 7-9 parts of grass, 1-2 parts of ginkgo leaf, 2-3 parts of purple perilla, 2-4 parts of bidens pilosa, 13 parts of Gynura bicolor, red-spotted stonecrop three
The mixture of seven 6-8 parts and small winged lotus 2-4 parts of extract.
7. application alpha-glucosidase restrainer prepares the medicine for preventing and treating type II diabetes as claimed in claim 5, its
It is characterised by, counts by weight, count by weight, second active ingredient of Chinese herbs is 15 parts of radix glycyrrhizae, 17 parts of the wind-weed, mulberry
22 parts of leaf, 3 parts of the root of kudzu vine, 15 parts of corn stigma, 6 parts of the coptis, 16 parts of the dried rhizome of rehmannia, 4 parts of Chinese cassia tree, 2 parts of Inonotus obliquus, 28 parts of dandelion, OK
7 parts of army's grass, 2 parts of ginkgo leaf, 2 parts of purple perilla, 4 parts of bidens pilosa, 13 parts of Gynura bicolor, 8 parts of aizoon stonecrop and small winged 2 parts of lotus
The mixture of extract.
8. the application alpha-glucosidase restrainer as any one of claim 4-7 is prepared for preventing and treating type II diabetes
Medicine, it is characterised in that the formulation of the medicine be selected from through gastrointestinal administration formulation or injecting medicine-feeding form.
9. application alpha-glucosidase restrainer prepares the medicine for preventing and treating type II diabetes as claimed in claim 8, its
It is characterised by, the medicine also includes being mixed with pharmaceutically acceptable auxiliary material.
10. application alpha-glucosidase restrainer prepares the medicine for preventing and treating type II diabetes as claimed in claim 9, its
It is characterised by, the auxiliary material is selected from solvent, propellant, solubilizer, cosolvent, emulsifying agent, binder, disintegrant, filler, profit
Lubrication prescription, wetting agent, osmotic pressure regulator, stabilizer, glidant, flavouring, preservative, suspending agent, coating material, aromatic,
Anti- binder, integrated agent, penetration enhancer, pH value regulator, buffer, plasticizer, surfactant, foaming agent, defoamer,
It is any in thickener, inclusion agents, NMF, absorbent, diluent, flocculant and deflocculant, filter aid, release retarding agent
It is one or more of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710403890.4A CN107088199B (en) | 2017-06-01 | 2017-06-01 | Alpha-glucosidase restrainer and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710403890.4A CN107088199B (en) | 2017-06-01 | 2017-06-01 | Alpha-glucosidase restrainer and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107088199A true CN107088199A (en) | 2017-08-25 |
| CN107088199B CN107088199B (en) | 2018-06-05 |
Family
ID=59638939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710403890.4A Expired - Fee Related CN107088199B (en) | 2017-06-01 | 2017-06-01 | Alpha-glucosidase restrainer and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107088199B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3163639A (en) * | 1962-01-24 | 1964-12-29 | Burroughs Wellcome Co | 4-thio-2'-deoxyuridine |
| CN102675389A (en) * | 2011-03-08 | 2012-09-19 | 大连大学 | 5-iodine-4-sulfur-2'-deoxyuridine, and derivatives and synthetic method thereof |
| DE102012111674A1 (en) * | 2012-11-30 | 2014-06-05 | Universität Rostock | New nucleoside derivatives useful for treating diabetes mellitus, which is used with further active substances |
-
2017
- 2017-06-01 CN CN201710403890.4A patent/CN107088199B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3163639A (en) * | 1962-01-24 | 1964-12-29 | Burroughs Wellcome Co | 4-thio-2'-deoxyuridine |
| CN102675389A (en) * | 2011-03-08 | 2012-09-19 | 大连大学 | 5-iodine-4-sulfur-2'-deoxyuridine, and derivatives and synthetic method thereof |
| DE102012111674A1 (en) * | 2012-11-30 | 2014-06-05 | Universität Rostock | New nucleoside derivatives useful for treating diabetes mellitus, which is used with further active substances |
Non-Patent Citations (2)
| Title |
|---|
| XIAOHUI ZHANG: "NMR and UV Studies of 4-Thio-2"-deoxyuridine and Its Derivatives", 《MOLECULES》 * |
| 张燕等: "糖尿病的中医病机与治法", 《中医药临床杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107088199B (en) | 2018-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102273621B (en) | A kind of food of prevention and therapy diabetes or health food | |
| US20120231097A1 (en) | Medicinal composition and usage | |
| CN104688822A (en) | Tablet for assisting to reduce blood glucose and preparation method | |
| CN104971190A (en) | Application of dioscorea cirrhosa in preparation of medicines for preventing or treating diabetes and complications of diabetes | |
| US10561700B2 (en) | Use of overground part of Hedychium coronarium Koenig in reducing blood glucose; extracts and compositions of overground part of Hedychium coronarium Koenig and their uses | |
| TWI678211B (en) | Uses of cistanche tubulosa extract and isoacteoside in protecting muscles | |
| CN100512796C (en) | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method | |
| EP2567704A1 (en) | Traditional chinese medicine composition for treating diabetes and preparation method thereof | |
| CN106798854B (en) | Phyllanthus emblica leaf and preparation method thereof | |
| CN107088199B (en) | Alpha-glucosidase restrainer and its application | |
| CN101264203B (en) | Chinese and western medicine composition for treating diabetes | |
| CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN103536879B (en) | A kind of pharmaceutical composition and preparation method for the treatment of diabetes | |
| CN103083423A (en) | Traditional Chinese prescription for treating hyperglycemia and preparation method thereof | |
| CN109248259A (en) | A kind of pueraria lobata extract tablet and preparation method thereof | |
| CN101036714B (en) | Medicinal composition for treating and/or preventing diabetes | |
| CN101322762B (en) | Medicinal composition for treating diabetes | |
| CN100363000C (en) | Chinese and western medicines composition contg. Avandia and its prepn. method | |
| CN102161619B (en) | Ferulic acid Jiangtang compound salt as well as preparation method and application thereof | |
| CN101810684B (en) | Synergic medicinal composition containing traditional Chinese medicine extract | |
| CN105343055A (en) | Pharmaceutical composition containing metformin and schisandrin b and treating diabetes | |
| KR20170064023A (en) | A composition comprising the extract of helianthus tuberosus for preventing, improving or treating the impairment of pancreatic beta cells | |
| CN100362998C (en) | Medicine composition for treating diabetes | |
| CN100362988C (en) | Chinese and western medicine composition contg. metformin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180605 Termination date: 20190601 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |